Pharmaceuticals Market Research Reports & Industry Analysis

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cholesterol Absorption Inhibitor The report ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cholesterylester Transfer Protein (CETP) Inhibitor The ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CRF1 Receptor Antagonist The report assesses ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CXCR4 Inhibitor The report assesses the active CXCR4 Inhibitor ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 1 (CDK1) Inhibitor The report ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 2 (CDK2) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor The ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 9 (CDK9) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclophilin Inhibitor The report assesses ...

... description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor The ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) The ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cytochrome P450 Superfamily (CYP or CYP450) Inhibitor The ...

... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cytochrome P450 17 (CYP17) Inhibitor The report ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D Agonist The report assesses the active D Agonist pipeline ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D Antagonist The report assesses the active D Antagonist pipeline ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D1 Agonist The report assesses the active D1 Agonist pipeline ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D1 Antagonist The report assesses the active D1 Antagonist pipeline ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D2 Agonist The report assesses the active D2 Agonist pipeline ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D3 Agonist The report assesses the active D3 Agonist pipeline ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D3 Antagonist The report assesses the active D3 Antagonist pipeline ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D4 Agonist The report assesses the active D4 Agonist pipeline ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D4 Antagonist The report assesses the active D4 Antagonist pipeline ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Delta Antagonist The report assesses the active Delta Antagonist ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Diglyceride Acyltransferase (DGAT) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dihydroorotate Dehydrogenase (DHODH) Inhibitor The ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DNA Methyltransferase Inhibitor The report assesses the active DNA ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DNA-Dependent RNA Polymerase Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dopaminergic Agonist The report assesses ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dopaminergic system Antagonist The report assesses ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DP1 Receptor (Prostaglandin D2 receptor) Antagonist The ...

... encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DP2 Receptor (G Protein-Coupled Receptor 44 or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Eg5 Inhibitor The report assesses the active Eg5 Inhibitor pipeline ...

... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Elastase Inhibitor ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Endothelin Receptor (ET) Antagonist The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Endothelin Receptor A (ETA) Antagonist The report ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Enhancer of zeste homolog 2 (EZH2) Inhibitor The report ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ephrin (EPH) Receptor Antagonist The report ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ephrin Type A Receptor 2 (EPH Receptor A2 or EPHA2) Antagonist ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Epithelial Sodium Channel (ENaC) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Estrogen Receptor Beta Partial Agonist The report ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor II (Prothrombin) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IIa (Thrombin) Inhibitor The report assesses ...

... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IX The report assesses the active Factor IX pipeline ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IX A Inhibitor The report assesses ...

... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor VIIa Inhibitor The report assesses the active Factor VIIa ...

... of Ablynx and SHP655 of Shire. Products covered by Phase Filed & Phase III Inactive (Dormant and Discontinued) Overview of pipeline development activities for Factor VIII Inhibitor Pipeline analysis of therapeutic drugs include but are ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Farnesoid X Receptor (FXR) Agonist The report ...

... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fatty Acid Amide Hydrolase (FAAH) Inhibitor The report ...

... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fatty Acid Synthase (FAS) Inhibitor The report ...

... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fc-Gamma Receptor Antagonist The report assesses ...